Best Agrolife Q2 FY27 Earnings Call — Analysis (NSE: BESTAGRO)
Best Agrolife reported Q2FY27 PAT growth of 48% YoY to ₹57 Cr despite a 21% revenue drop to ₹407 Cr, driven by an intentional mix shift toward higher-margin patented molecules and strict cost control.
Result quality: stable — Results context unavailable. Management sentiment: neutral.
The take
Q2FY27 Revenue from Operations ₹407 Cr ( -21.28% YoY ) . Guidance cut — FY27 h2 fy27 net profit after tax po… no loss / positive PAT . But walked back — Capex pause and resetting growth ambition . New story: Shift to patented product portfolio .
Results
Revenue fell 21.3% YoY to ₹407 Cr, while EBITDA rose 29.5% YoY to ₹101 Cr with margin expanding 1,000 bps to 25%, and PAT grew 46.2% YoY to ₹57 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from Operations | ₹407 Cr | -21.28% | yoy · Q2FY27 · Q2FY26 ₹517 Cr |
| Gross Margin | 45% | +1200bps | yoy · Q2FY27 · Q2FY26 33% |
| EBITDA | ₹101 Cr | +29.49% | yoy · Q2FY27 · Q2FY26 ₹78 Cr |
| EBITDA Margin | 25% | +1000bps | yoy · Q2FY27 · Q2FY26 15% |
| Profit After Tax | ₹57 Cr | +46.15% | yoy · Q2FY27 · Q2FY26 ₹39 Cr |
| PAT Margin | 14% | +600bps | yoy · Q2FY27 · Q2FY26 8% |
| H1 Revenue from Operations | ₹803 Cr | -10.58% | yoy · H1FY27 · H1FY26 ₹898 Cr |
| H1 EBITDA | ₹178 Cr | +44.72% | yoy · H1FY27 · H1FY26 ₹123 Cr |
| H1 Profit After Tax | ₹98 Cr | +66.10% | yoy · H1FY27 · H1FY26 ₹59 Cr |
| Operating Expenses (excl. Fin & Dep) | ₹81 Cr | -11.96% | yoy · Q2FY27 · Q2FY26 ₹92 Cr |
Guidance
Management expects to avoid losses in H2FY27 by booking higher sales return provisions and targeting full-year revenue close to FY26 levels while expanding profitability.
What management committed to
- The company should not have losses in H2 FY27. — no loss / positive PAT, FY27
Key themes
Patented portfolio transition over generic volume
How the narrative shifted
- Monsoon uncertainty and demand recovery: Narrative evolved from cautiously optimistic to region-specific account of shortfalls; no major reframing.
- Shift to patented product portfolio: Strategy validated by verified data; no reframing needed.
- Profitability over volume growth: Translated from stated intent to proven outcome.
- Disciplined inventory and working capital management: Explicit buffer mechanism introduced to absorb return risk.
- Capex pause and resetting growth ambition: Growth ambition further de-emphasized with direct admission that prior CAGR may not be achievable.
- International registration pipeline: Moving from registration milestones to early revenue and operational presence.
- Geopolitical disruptions and input cost inflation: Newly introduced; presented as a manageable external shock requiring prudent financial adjustment.
Operational commentary
- Patented products share in revenue increased from 50% in H1FY26 to 60% in H1FY27, while generic sales were intentionally cut by 30%.
- Launched new patented products Midcotin (insecticide+fungicide for paddy) and SECTOR (insecticide for pomegranate and chili) during the quarter.
- Granted patent for a triple-combination insecticide molecule (Fluxametamide + Abamectin + Trifloxystrobin).
- Progressed foreign patent filings (Ronfen, Nano Urea, Fluxametamide, Flonicamid, Abamectin combinations) to examination stage in UAE, Vietnam, Sri Lanka, Philippines, and Egypt.
- Secured 13 CIB registrations in India, export registration for Ronfen in Nepal, Lambda registration in Mexico, and shipped 47 MT consignment to Sudan.
- Incorporated a wholly owned step-down subsidiary in Brazil through Best Agrolife Global to target South American agrochemical markets.
- B2B licensing of proprietary patented molecules expanded to multinational partners including SWAL Corporation (UPL subsidiary) and Adama.
Analyst Q&A
Q. Why did institutional sales drop by ₹88 Cr while B2C sales dropped by only ₹22 Cr?
The drop was intentional as management actively curtailed low-margin generic B2B sales to shift toward specialized and patented molecules, driving patented mix up by 20% and gross margins higher.
Q. How will management prevent unexpected sales returns and losses in H2FY27 like last year?
Strict deadlines were enforced requiring sales returns to be logged by end-October (95% already collected), and higher provisions/margin buffers were established in Q2.
Q. Why did long-term borrowings increase from ₹27 Cr in March to ₹73 Cr if capex is deferred?
The company availed an emergency 20% government credit support facility (~₹50 Cr across group) amid rising inventory costs due to geopolitical tensions; funds are used for working capital with a 1-year moratorium.
Q. Will management meet its previously guided 10-15% annual top-line growth target?
Management acknowledged that 10-15% growth is difficult this year due to rainfall deficits and intentional shedding of generics, stating they are not chasing revenue at the expense of profitability.
Research and educational content only. Not investment advice.